Viking Therapeutics
VKTX
7 hedge funds and large institutions have $158K invested in Viking Therapeutics in 2015 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
37% less capital invested
Capital invested by funds: $252K → $158K (-$94K)
Top Buyers
| 1 |
Wells Fargo
San Francisco,
California
|
+$28.1K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$14K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.69K |
| 4 |
Morgan Stanley
New York
|
+$76 |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$24.4K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $64K | +$2.69K | +600 | +3% |
|
|
2
Goldman Sachs
New York
| $44K | -$24.4K | -5,436 | -30% |
|
|
3
Wells Fargo
San Francisco,
California
| $21K | +$28.1K | +6,250 | New |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $18K | +$14K | +3,125 | New |
|
5
Creative Planning
Overland Park,
Kansas
| $10K | – | – | – |
|
|
BIM
6
BlackRock Investment Management
Wilmington,
Delaware
| $1K | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$11K | -1,903 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$8K | -1,408 | Closed |
|
|
9
Morgan Stanley
New York
| – | +$76 | +17 | New |
|
VKTX Hedge Fund Activity: Q4 2015 in Review
7 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2015, worth a combined $158K — down 37% from $252K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VKTX positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Wells Fargo, opening a new position worth an estimated $28.1K. The largest seller was Goldman Sachs, cutting an estimated $24.4K.
- 7 institutional investors held Viking Therapeutics (VKTX) as of Q4 2015, up from 6 in Q3 2015.
- Funds reported $158K of Viking Therapeutics stock for Q4 2015, down 37% quarter-over-quarter.
- 3 funds opened new Viking Therapeutics positions in Q4 2015 and 2 closed out, a net change of +1 holder.
- The largest Viking Therapeutics buyer in Q4 2015 was Wells Fargo, an estimated $28.1K added.
- The largest Viking Therapeutics seller in Q4 2015 was Goldman Sachs, an estimated $24.4K sold.
Based on aggregated 13F filings for Q4 2015.